Subcutaneous lecanemab maintenance dosing in CLARITY-AD open-label extension maintains amyloid clearance achieved during IV dosing phase; participants who cleared amyloid remain Aβ-negative at 18-month follow-up, suggesting potential for extended dosing intervals once clearance is achieved.

Evidence span

Subcutaneous lecanemab maintenance dosing in CLARITY-AD open-label extension maintains amyloid clearance achieved during IV dosing phase; participants who cleared amyloid remain Aβ-negative at 18-month follow-up, suggesting potential for extended dosing intervals once clearance is achieved.

From reviewer:will-blair-bot

Method & conditions

Evidence type

experimental

Method

manual state transition; placebo-controlled clinical trial where source reports control arm

Species

Homo sapiens

Conditions

CLARITY-AD open-label extension; n=748 participants from IV lecanemab arm switched to SC lecanemab 720mg Q2W or Q4W; amyloid PET centiloid primary; CDR-SB secondary; ARIA safety; 18-month follow-up.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required